Organon, Samsung Bioepis launch HUMIRA biosimilar HADLIMA in US
Organon & Co. and Samsung Bioepis revealed that HADLIMA (adalimumab-bwwd), a biosimilar referencing Humira (adalimumab), is now accessible to patients in the United States. This ... Read More
Pfizer, AbbVie settle global IP for Humira biosimilar, paving way for European launch
In a significant step towards expanding biosimilar access, Pfizer and AbbVie have resolved all global intellectual property disputes concerning Pfizer’s proposed biosimilar to AbbVie’s blockbuster ... Read More
Mylan launches Hulio, a biosimilar to Humira, across major European markets
Mylan has officially launched Hulio, its biosimilar to AbbVie’s Humira (adalimumab), across major European markets. This launch follows the European Commission's recent approval of Hulio ... Read More
Boehringer Ingelheim’s Cyltezo achieves clinical equivalence to Humira in Phase 3 psoriasis trial
German pharmaceutical giant Boehringer Ingelheim has announced a significant milestone in the treatment of moderate-to-severe chronic plaque psoriasis. Their drug, Cyltezo, a biosimilar to AbbVie's ... Read More
Novartis’ Sandoz gains EC approval for biosimilar Hyrimoz across multiple therapeutic areas
In a significant advancement for biopharmaceuticals, Novartis' division Sandoz has secured approval from the European Commission (EC) for Hyrimoz (adalimumab), a biosimilar to AbbVie’s Humira. ... Read More